The impact of palbociclib (Ibrance) on overall survival for metastatic breast cancer patients in the PALOMA-3 trial
Full article:

The PALOMA-3 clinical trial showed that a new CDK4/6 inhibitor in combination therapy improved progression-free survival of women treated for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in women with prior disease progression after endocrine therapy. This XRAYS reviews a newly published study in the New England Journal of Medicine that looks at overall survival in the original PALOMA-3 study. (1/23/19)

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following studies look at treatment for people with metastatic ER-positive breast cancer.  

Other clinical trials for people with breast cancer can be found here.

The following studies are looking at treatment for people with advanced solid tumors. 



FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.